Monograph Details
|
|
Urogenital System
> Overactive bladder/enuresis
|
|
VESICARE |
| Manufacturer |
|
Astellas Pharma US, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antispasmodic/anticholinergic. |
| Generic Name |
|
Solifenacin succinate 5mg, 10mg; tabs. |
| Indications |
|
Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. |
| Children |
|
Not recommended. |
| Adults |
|
Swallow whole with liquids. Initially 5mg once daily; if well tolerated, may increase to 10mg once daily. Severe renal impairment (CrCl<30mL/min), moderate hepatic impairment, or concomitant potent CYP3A4 inhibitors (eg, ketoconazole): max 5mg once daily. |
| Contraindications |
|
GI or urinary retention. Uncontrolled narrow-angle glaucoma. Severe hepatic impairment. |
| Precautions |
|
Bladder outflow obstruction. GI obstructive disorders. Decreased GI motility. Controlled narrow-angle glaucoma. QT prolongation. Exposure to high environmental temperature. Renal or hepatic insufficiency. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Additive anticholinergic effects with other anticholinergics. Potentiated by potent CYP3A4 inhibitors (eg, ketoconazole). |
| Adverse Reactions |
|
Anticholinergic effects (eg, dry mouth, constipation, blurred vision), dyspepsia. |
| How Supplied |
|
Tabs—30, 90 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
